In Brief This Week: Nanosphere; Oxford BioDynamics, Janssen; Horizon Discovery; Eagle; Gentris | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere this week received the CE IVD Mark for its Gram-Negative Blood Culture test that runs on the firm's Verigene molecular diagnostics platform. The Verigene BC-GN test provides rapid genus and species level detection for a broad panel of clinically significant gram-negative bacteria, said Nanosphere. It also detects critical genetic markers of antimicrobial resistance including KPC, NDM, CTX-M, OXA, VIM, and IMP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.